Long-term bone-marrow damage in children treated for ALL: evidence from in vitro colony assays (GM-CFC and CFUF).
We have studied granulocyte-macrophage progenitor cells (GM-CFC) in serial bone marrow aspirates from 43 children who had been treated for acute lymphoblastic leukaemia (ALL). All patients were in full remission, not receiving anti-leukaemic therapy and 42 out of the 43 had normal peripheral blood counts. Thirty-seven patients have received standard amounts of chemotherapy and 6 have received additional therapy for relapses occurring in the first treatment-free interval. In the former group estimation of GM-CFC incidence did not provide evidence of long-term residual bone-marrow damage. In the latter, however, the mean incidence of GM-CFC was significantly reduced. This reduction was also apparent when the incidence of GM-CFC was related to the incidence of non-haemopoietic progenitor cells within the marrow (CFU-F).
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000473:pathology; D001855:Bone Marrow Diseases / Q000139:chemically induced* / Q000473:pathology; D002648:Child; D003114:Colony-Forming Units Assay; D005500:Follow-Up Studies; D006412:Hematopoietic Stem Cells / Q000473:pathology; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D007958:Leukocyte Count; D009504:Neutrophils; D010976:Platelet Count
D000970:Antineoplastic Agents; D006454:Hemoglobins